Huadong Medicine
Huadong Medicine Co., Ltd. (000963.SZ), headquartered in Hangzhou City, Zhejiang Province, was listed on the Shenzhen Stock Exchange in December 1999. Recognized by Forbes as one of the 50 Best Publicly Traded Companies in Asia-Pacific and listed in the Fortune China 500 for consecutive years, Huadong Medicine ranks 10th among China’s top 100 pharmaceutical companies. The company spans the entire pharmaceutical industry chain, focusing on four core segments: pharmaceutical development, pharmaceutical distribution, medical aesthetics, and microbiology. Today, it stands as a leading pharmaceutical enterprise specializing in innovative R&D, manufacturing, sales, and marketing.
Huadong Medicine specializes in the research, development, production, and sales of treatments for specialty, chronic, and rare diseases. We have established a comprehensive pharmaceutical manufacturing and quality assurance system, with a core product pipeline focusing on chronic kidney disease, autoimmune disorders, endocrinology, and oncology. Our portfolio includes several leading clinical drugs in the domestic market, and we have developed a complete pharmaceutical supply chain system for the international market. We collaborate with global innovators such as Pfizer and Takeda to better serve patients in China. Through internal drug development, external partnerships, and strategic collaborations, we focus on three core therapeutic areas: oncology, endocrinology, and autoimmune diseases.
Oncology
Huadong Medicine is dedicated to building a world-leading platform for innovative oncology drug development. We have established a pipeline of targeted small molecule drugs, ADCs, antibodies, and PROTACs, with over a dozen globally innovative drugs. For instance, in collaboration with ImmunoGen in the United States, we have developed ELAHERE®, the first ADC drug of its kind, intended for platinum-resistant ovarian cancer. Additionally, we have invested in, acquired, and incubated multiple biotech companies with cutting-edge technology both domestically and internationally, creating a unique ADC global R&D ecosystem to drive the development of differentiated ADC therapies.
Endocrinology
We have established a comprehensive pipeline of innovative and differentiated solutions targeting key therapeutic areas in diabetes, with 20+ drugs commercialized and in-development. Specifically, Huadong Medicine has developed a broad GLP-1 product line that includes multiple dosage forms—both oral and injectable—as well as long-acting and multi-target global innovations and biosimilars. Our liraglutide injection received NMPA approval for diabetes in March 2023 and for obesity or overweight indications in June 2023, making it the first domestically produced option in China for these indications.
Autoimmunity
Huadong Medicine has become one of the most comprehensive pharmaceutical companies in China within the field of autoimmune diseases. We have 10+ innovative biologics and small molecule drugs in development and have established a specialized topical formulation platform. Our diverse pipeline covers various indications and specialties, including dermatology, orthopedics, and rheumatology. With strong capabilities in topical formulation development, registration, production, and commercialization, we deliver integrated solutions to meet the needs of patients and healthcare providers.
Huadong Medicine ranks among China’s top 10 pharmaceutical distributors, serving 11 cities and 90 districts across the country. We utilize integrated wholesale and retail capabilities, advanced logistics, and a proprietary e-commerce platform to distribute pharmaceutical drugs, traditional Chinese medicine, medical devices, herbal medicines, and health and wellness products.
Huadong Medicine’s wholly-owned subsidiary, Sinclair Aesthetics, is a global medical aesthetics company headquartered in the UK. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies in both the injectable and EBD segments. Both divisions are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The company has an established sales and marketing presence in over 55 countries, including U.S., China, EU markets, Brazil, Mexico, Colombia, UAE and South Korea.
Huadong Medicine has a solid foundation and extensive expertise in microbiology, successfully developing and manufacturing a range of microbial-based drugs that meet industry-leading standards. We focus on advancing synthetic biology and biopharmaceutical innovation, building a diverse product pipeline and customized solutions in four key areas: xRNA, specialty APIs & intermediates, wellness & biomaterials, and animal health.